Related Experiment Video
Updated: Oct 11, 2026

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice
Published on: July 4, 2018
Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis
1Child Health, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK, NG5 1PB. Kelvin.Tan@nottingham.ac.uk
Background:
Patients with cystic fibrosis, who are chronically colonised with the organism Pseudomonas aeruginosa, often require repeated courses of intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations. The properties of aminoglycosides suggest that they could be given in higher concentrations less often.
Objectives:
To assess the effectiveness and safety of once-daily versus multiple-daily dosing of intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations in cystic fibrosis.
Search Strategy:
We searched the Cystic Fibrosis specialist trials register held at the Cochrane Cystic Fibrosis and Genetic Disorders Group's editorial base, which comprises references identified from comprehensive electronic database searches, handsearching relevant journals and handsearching abstract books of conference proceedings. Date of the most recent search: February 2000.
Selection Criteria:
All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared with multiple-daily dosing in terms of efficacy and/or toxicity, in patients with cystic fibrosis.
Data Collection And Analysis:
Both reviewers independently extracted data and assessed trial quality. Authors of one study were contacted to obtain missing information.
Main Results:
Two trials reporting results from a total of 70 patients were included in this review. Both trials compared once-daily dosing with thrice-daily dosing reporting data on Forced Expiratory Volume at one second (FEV1), Forced Vital Capacity (FVC), nutritional status and side effects. There was no significant difference in efficacy or in the incidence of ototoxicity and nephrotoxicity between treatment groups.
Reviewer'S Conclusions:
Despite a lack of difference between the two groups we feel that these results should be viewed with caution as the numbers of patients involved was small and lacks the power to detect a difference between the groups. This systematic review has highlighted the need for a well designed, adequately-powered, multicentre, randomised controlled trial assessing the efficacy of once-daily versus multiple-daily dosing of intravenous aminoglycosides for pulmonary exacerbations in cystic fibrosis.
Insights
Once-daily aminoglycoside antibiotics are as effective and safe as multiple daily doses for cystic fibrosis pulmonary exacerbations, but larger trials are needed. This finding impacts antibiotic dosing strategies for Pseudomonas aeruginosa infections in CF patients.
Area of Science:
- Pulmonology
- Infectious Diseases
- Pharmacology
Background:
- Cystic fibrosis (CF) patients often have chronic Pseudomonas aeruginosa colonization.
- Pulmonary exacerbations in CF commonly require intravenous aminoglycoside antibiotics.
- Aminoglycoside properties suggest potential for less frequent, higher-dose administration.
Purpose of the Study:
- To evaluate the efficacy and safety of once-daily versus multiple-daily intravenous aminoglycoside dosing.
- To assess antibiotic treatment strategies for CF pulmonary exacerbations.
Main Methods:
- Systematic review of randomized controlled trials comparing aminoglycoside dosing regimens.
- Searched specialized CF trials registers and electronic databases (search up to February 2000).
- Independent data extraction and quality assessment by reviewers.
Main Results:
- Two trials with 70 patients compared once-daily with thrice-daily aminoglycoside dosing.
- No significant differences observed in efficacy (FEV1, FVC, nutritional status) or toxicity (ototoxicity, nephrotoxicity).
Conclusions:
- Current evidence suggests similar efficacy and safety between once-daily and multiple-daily aminoglycoside dosing for CF pulmonary exacerbations.
- Small patient numbers necessitate caution; larger, well-powered trials are required.
- Highlights the need for robust research into optimal aminoglycoside dosing in CF.
More Related Videos
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Estimation of k and VD of Aminoglycosides
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Dosage Regimen: Multiple Oral Dosage
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...